Excidium Research

  • We analysed the performance of equity research analysis available on Bloomberg. Out of 70 firms, only one research firm was profitable.

    Full analysis presetation available: excidium.co.uk/analystperformance

  • Milestone Pharmaceuticals aims to treat Paroxysmal Supraventricular Tachycardia (PSVT) with their lead asset etripamil - an intranasaly administered calcium channel blocker.

    Full coverage available at excidium.co.uk/milestone

  • Excidium Research initiates SELL rating on INMUNE Bio Inc, a company targeting Alzheimer’s Disease with soluble Tumour Necrosis Factor.

    excidium.co.uk/inmune

    1 Mar


  • Following a Fox news interview , SELLAS has rallied to all time highs. The movement is not backed by an increase in fair value.

    excidium.org/sellas

    27 Jan

  • Excidium initiates coverage on SELLAS Life Sciences with a SELL rating. Full thesis can be found at excidium.org/sellas

    25 Jan

  • Initiating coverage on Anavex Life Sciences posted at excidium.org/anavex

    9 Jan

We target small and microcap biopharmaceuticals companies where our advantage is greatest and mispricing is most intense.

These young, often clinical stage companies have little to no institutional attention. Analyst coverage is often done by investment banks with vested interests in the company but often result in material market movements. Retail also comprises the majority of the public ownership and the price resultantly and predictably overweights immaterial information.

We place great emphasis on clinical information and our team of young and specialised analysts is made mostly of high ranking Life Sciences students at top UK universities.

We hope to be able to change the status-quo of clinical stage equity research, where analyst coverage is really inaccurate due to lacking capacity in the space.

Transparency is in every piece of work we do. Each article published on our site will be timestamped using blockchain via opentimestamps.org to ensure verifiability.